



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

Fax Cover Sheet

Date: 15 Dec 2004

To: Jeff Peter	From: Theodore J. Criares
Application/Control Number: 09/995,911	Art Unit: 1617
Fax No.: 1-608-283-2275	Phone No.: (571) 272-0625
Voice No.: (608) 257-3501	Return Fax No.: (703) 872-9306
Re:	CC:

☒ **Urgent** ☐ **For Review** ☐ **For Comment** ☐ **For Reply** ☒ **Per Your Request**

Comments:

Executed IDS 1449 for 9/8/03; 11/21/03; 3/3/04 and 4/10/04.

Number of pages __ **including this page**

STATEMENT OF CONFIDENTIALITY

This facsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SEP 08 2003

PTO/SB/08A
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 09/995,911
Filing Date November 28, 2001
First Name Inventor Richard B. Mazess
Group Art Unit 1617
Examiner Name Criares, Theodore
Attorney Docket Number 017620-9335

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
RE	6,143,910	BISHOP et al.	11/7/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract

Q:\client\017620\9335\B0244793.1
09/04/03


Examiner Signature		Date Considered	12/17/04
-----------------------	---	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute of form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	09/995,911
		Filing Date	November 28, 2001
		First Name Inventor	Mazess et al.
		Group Art Unit	1617
		Examiner Name	Theodore J. Criares
		Attorney Docket Number	017620-9335
Sheet 1 of 2			

RECEIVED
DEC 02 2003
TECH CENTER 1600/2800

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
-------------------	-----------------------------	---	---------------------------------------


BA	4,160,803	Potts	07/10/79
BB	4,717,721	DeLuca et al.	01/25/88
BC	4,902,481	Clark et al.	02/20/90
BD	5,141,719	Fernwood et al.	08/25/92
BE	5,205,989	Aysta	04/27/93
BF	5,219,528	Clark	06/15/93
BG	5,232,836	Bouillon et al.	08/03/93
BH	5,264,184	Aysta et al.	11/23/93
BI	5,264,618	Felgner et al.	11/23/93
BJ	5,334,740	Takahashi et al.	08/02/94
BK	5,338,532	Tomalia et al.	08/16/94
BL	5,417,923	Bojanic et al.	05/23/95
BM	5,527,524	Tomalia et al.	06/18/96
BN	5,554,386	Groman et al.	09/10/96
BO	5,597,575	Breitbarth	01/28/97
BP	5,614,513	Knutson et al.	03/25/97
BQ	5,637,742	Valles et al.	06/10/97
BR	5,661,025	Szoka, Jr. et al.	08/26/97
BS	5,691,328	Peterson et al.	11/25/97

Examiner Signature		Date Considered	12/14/04
--------------------	---	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/995,911
		Filing Date	November 28, 2001
		First Name Inventor	Mazess et al.
		Group Art Unit	1617
Examiner Name	Theodore J. Criares		
Sheet 2 of 1	Attorney Docket Number	017620-9335	

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
-------------------	-----------------------------	---	---------------------------------------

BT	5,739,271	Sridhar et al.	04/14/98
BU	5,795,882	Bishop et al.	08/18/98
BV	5,798,345	Knutson et al.	08/25/98
BW	6,503,893	Bishop et al.	01/07/03
BX	6,521,608	Henner et al.	02/18/03
BY	6,537,982	Bishop et al.	03/25/03
BZ	6,538,037	Bishop et al.	03/25/03

FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
CA	Japan	5320127	Nisshin Flour Milling Co.	09/29/93		
CB	Japan	6025039	Kurary Co. Ltd.	02/01/94		
CC	Japan	62000033	General Hospital	10/15/86		
CD	PCT	WO 93/07883	ISIS Pharmaceuticals	04/29/93		


Q:\client\017620\9335\B0265972.1

Examiner Signature		Date Considered	12/14/02
--------------------	--	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form PTO/SB/08B			Complete if Known		
			Application Number	09/995,911	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	November 28, 2001	
			First Named Inventor	Mazess et al.	
			Group Art Unit	1617	
			Examiner Name	Theodore J. Criares	
			Attorney Docket Number	017620-9335	
Sheet	1	of	2		

RECEIVED
DEC 02 2003
TECH CENTER 1600/2300

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
-------------------	---

PK	CE	Beer, T. et al., "Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer," <i>Journal of Clinical Oncology</i> , (Jan. 2003) 21:1:123-128.
	CF	Blazsek, I. et al. "Combined Differentiation Therapy in Myelodysplastic Syndrome with Retinoid Acid, 1 α ,25 Dihydroxyvitamin D ₃ , and Prednisone," 16:4:259-264 (Abstract).
	CG	Carter, Stephen K. et al. <i>Chemotherapy of Cancer</i> 2 nd Ed. (1981) 362-365.
	CH	Cho, Y.L. et al., "Combined Effects of 1,25-Dihydroxyvitamin D ₃ and Platinum Drugs on the Growth of MCF-7 Cells," <i>Cancer Research</i> , (June 1991) 51:2848-2853.
	CI	Defacque, H. et al., "Different Combinations of Retinoids and Vitamin D ₃ Analogs Efficiently Promote Growth Inhibition and Differentiation of Myelomonocytic Leukemia Cell Lines," <i>J. Pharmacology and Experimental Therapeutics</i> , (1994) 271:193-199.
	CJ	Endo, K. et al., "Effect of Combination Treatment with Vitamin D Analog (OCT) and a Bisphosphonate (AHPrBP) in a Nude Mouse Model of Cancer-Associated Hypercalcemia," <i>Journal of Bone and Mineral Research</i> , (1998) 13:9:1378-1383.
	CK	Hershberger, P. et al. "Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity <i>in Vitro</i> and <i>in Vivo</i> and Accelerates Paclitaxel-induced Apoptosis," <i>Clinical Cancer Research</i> , (April 2001) 7:1043-1051.
	CL	Johnson, C. et al., "Vitamin D-related Therapies in Prostate Cancer," <i>Cancer and Metastasis Review</i> 21, (2002) pp. 147-158.
	CM	<i>Journal of Bone and Mineral Research</i> , (1994) 9:5:607-614.
	CN	Kim, S. et al., "Potentiation of 1,25-Dihydroxyvitamin D ₃ -Induced Differentiation of Human Promyelocytic Leukemia Cells into Monocytes by Costunolide, a Germacranolide Sesquiterpene Lactone," <i>Biochem. Pharmacology</i> , (2002) 64:1233-1242.
	CO	Londowski, J.M. et al., "Biological Activity of the C-1, C-3, C-25, β -D-Glucopyranosides of 1,25-Dihydroxyvitamin D ₃ ," <i>J. Pharmacology Expr. Ther.</i> , (1986) 237:3:837-840.
	CP	Mathias, C.J. et al., "Tumor-Selective Radiopharmaceutical Targeting Via Receptor-Mediated Endocytosis of Gallium-67-Deferoxamine-Folate," <i>J. Nucl. Med.</i> (1996), 37(6):1003-1008.
	CQ	Moffatt, K. et al., "1 α ,25-Dihydroxyvitamin D ₃ and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines," <i>Clinical Cancer Research</i> , (March 1999) 5:695-703.
	CR	Muindi, J. et al., "Pharmacokinetics of High-Dose Oral Calcitriol: Results From a Phase I Trial of Calcitriol and Paclitaxel," <i>Clinical Pharmacology & Therapeutics</i> , (Dec. 2002) pp. 648-659.

Examiner Signature		Date Considered	12/14/04
--------------------	--	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/995,911
			Filing Date	November 28, 2001
			First Named Inventor	Mazess et al.
			Group Art Unit	1617
			Examiner Name	Theodore J. Criares
			Attorney Docket Number	017620-9335
Sheet	2	of	2	

RECEIVED
DEC 02 2003
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.


CS	Packman, K. et al. "Combination Treatment of MCF-7 Xenografts with the Vitamin D ₃ Analog EB1089 and Antiestrogens," (Vitamin D Endocrine Workshop, Nashville, TN May 27-June 1, 2000) pp. 511-514.
CT	Ravid, A. et al., "1,25-Dihydroxyvitamin D ₃ Enhances the Susceptibility of Breast Cancer Cells to Doxorubicin-induced Oxidative Damage," <i>Cancer Research</i> , (February 15, 1999) 59:862-867.
CU	Siwinska, A. et al. "Potentiation of the Antiproliferative Effect <i>in Vitro</i> of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D," <i>Anticancer Research</i> , (2001) 21:1925-1929.
CV	Slapak, C. et al., "Treatment of Acute Myeloid Leukemia in the Elderly with Low-Dose Cytarabine, Hydroxyurea, and Calcitriol," <i>Amer. J. Hematology</i> , (1992) 41:178-183.
CW	Song, X.D. et al., "Bryostatin-1 and 1 α ,25-Dihydroxyvitamin D ₃ Synergistically Stimulate the Differentiation of NB4 Acute Promyelocytic Leukemia Cells," <i>Leukemia</i> , (1999) 13:275-281.
CX	Studzinski, G. et al., "Potentiation by 1- α ,25-Dihydroxyvitamin D ₃ of Cytotoxicity to HL-60 Cells Produced by Cytarabine and Hydroxyurea," <i>J. National Cancer Inst.</i> , (April 1986) 76:4:641-648.
CY	Suzuki, Y. et al., "The Enhancement of the Chemotherapeutic Effects on Human Prostate Cancer Cell - The Combination with the Growth Factor Interaction Inhibitor (Suramin)," <i>Acta Urologica</i> (1993) 12:1215-1220, (Abstract).
CZ	Swami, S. et al. "1 α ,25-Dihydroxyvitamin D ₃ Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells," <i>Clinical Cancer Research</i> , (Aug. 2000) 6:3371-3379.
DA	Torres, R. et al., "Etoposide Stimulates 1,25-Dihydroxyvitamin D ₃ Differentiation Activity, Hormone Binding and Hormone Receptor Expression in HL-60 Human Promyelocytic Cells," <i>Molecular and Cellular Biochemistry</i> , (2000) 208:157-162.
DB	Wang, Q. et al., "1,25-Dihydroxyvitamin D ₃ and All-trans-Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death," <i>Cancer Research</i> , (April 2000) 60:2040-2048.
DC	Wang, X. et al., "Inhibition of p38 MAP Kinase Activity Up-Regulates Multiple MAP Kinase Pathways and Potentiates 1,25-Dihydroxyvitamin D ₃ -Induced Differentiation of Human Leukemia HL60 Cells," <i>Experimental Cell Research</i> , (2000) 258:425-437.
DD	Yu, W. et al., "Enhancement of 1,25-Dihydroxyvitamin D ₃ -Mediated Antitumor Activity with Dexamethasone," <i>J. National Cancer Inst.</i> , (January 1998) 90:2:134-141.

Q:\client\017620\9335\B0265973.1

Examiner Signature		Date Considered	12/14/04
--------------------	--	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	TREATMENT OF HYPERPROLIFERATIVE DISEASES USING ACTIVE VITAMIN D ANALOGUES						
Application Number:		09/995911					
Confirmation Number:		4126					
First Named Applicant:		Richard Mazess					
Attorney Docket Number:		0176209335					
Art Unit:		1617					
Examiner:		Theodore Criares					
Search string:		(6582710 or 6599513 or 6642218 or 20010002396 or 20010025036 or 20010049365 or 20010051617 or 20020006917 or 20020049344 or 20020068723 or 20020091109 or 20020099039 or 20020103173 or 20020132799 or 20030040508 or 20030109506 or 20030119795 or 20030149005 or 20030149006 or 20030166622 or 20030171342 or 20030195171 or 20030195176 or 20030195259 or 20030216359 or 20040019023).pn.					
US Patent Documents							
Note: Applicant is not required to submit a paper copy of cited US Patent Documents							
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
<input checked="" type="checkbox"/>	1	6582710	2003-06-24	Deckers et al			
<input checked="" type="checkbox"/>	2	6599513	2003-07-29	Deckers et al			
<input checked="" type="checkbox"/>	3	6642218	2003-11-04	Steinmeyer et al			
US Published Applications							
Note: Applicant is not required to submit a paper copy of cited US Published Applications							
init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
<input checked="" type="checkbox"/>	1	20010002396	2001-05-31	Achkar			
<input checked="" type="checkbox"/>	2	20010025036	2001-09-27	DeLuca et al			



12/14/04


12	3	20010049365	2001-12-06	Achkar
	4	20010051617	2001-12-13	DeLuca et al
	5	20020006917	2002-01-17	DeLuca et al
	6	20020049344	2002-04-25	Steinmeyer et al
	7	20020068723	2002-06-06	DeLuca et al
	8	20020091109	2002-07-11	Takenouchi et al
	9	20020099039	2002-07-25	Takenouchi et al
	10	20020103173	2002-08-01	Takenouchi et al
	11	20020132799	2002-09-19	Takenouchi et al
	12	20030040508	2003-02-27	DeLuca et al
	13	20030109506	2003-06-12	Hayes et al
	14	20030119795	2003-06-26	Henner et al
	15	20030149005	2003-07-07	Posner et al
	16	20030149006	2003-07-07	Steinmeyer et al
	17	20030166622	2003-09-04	Steinmeyer et al
	18	20030171342	2003-09-11	Posner et al
	19	20030195171	2003-10-16	Daifotis et al
	20	20030195176	2003-10-16	Kawase et al
	21	20030195259	2003-10-16	Bernardon et al
	22	20030216359	2003-11-20	Johnson et al
	23	20040019023	2004-01-29	Morikawa et al

Remarks

Note: Remarks are not for responding to an office action.

This is the second of two (2) electronic submissions and one paper filing submission (mailed March 2, 2004 with \$180 fee) of foreign patent documents and non-patent literature. All are considered to be part of the same, single IDS. Citation of these references is respectfully requested. Please charge or credit Deposit Account 50-0842 with any shortage or overpayment of the required fee. No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Signature



12/14/04

Examiner Name	Date



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	TREATMENT OF HYPERPROLIFERATIVE DISEASES USING ACTIVE VITAMIN D ANALOGUES						
Application Number: 09/995911							
Confirmation Number: 4126							
First Named Applicant: Richard Mazess							
Attorney Docket Number: 0176209335							
Examiner: Theodore Criares							
Search string: (4948789 or 5260290 or 5366965).pn.							
US Patent Documents							
Note: Applicant is not required to submit a paper copy of cited US Patent Documents							
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
<input checked="" type="checkbox"/>	1	4948789	1990-08-14	Slatopolsky			
<input checked="" type="checkbox"/>	2	5260290	1993-11-09	DeLuca et al			
<input checked="" type="checkbox"/>	3	5366965	1994-11-22	Strein			
Remarks							
Note: Remarks are not for responding to an office action.							
Citation of these references is respectfully requested. No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate. The commissioner is hereby authorized to charge any deficiency in the payment of the required fee or credit any overpayment to Deposit Account No. 50-0842..							
Signature							
Examiner Name				Date			
				12/14/04			